Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 4/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30280453 | 0.89 | PTPN11 (0.48) | PTPN11KCNH2PIK3CAHTR6MEN1 | |
| SCHEMBL30280376 | 0.89 | PTPN11 (0.50) | PTPN11KCNH2PIK3CAFLT3HTR6 | |
| SCHEMBL31396579 | 0.83 | PTPN11 (0.45) | PTPN11KCNH2RET | |
| SCHEMBL31396506 | 0.79 | PTPN11 (0.46) | PTPN11KCNH2HTR6RETMAP4K1 | |
| SCHEMBL30280389 | 0.79 | PTPN11 (0.49) | PTPN11KCNH2HTR6MAP4K1 | |
| SCHEMBL30280360 | 0.79 | PTPN11 (0.51) | PTPN11KCNH2PIK3CAPTGS1PTGS2 | |
| SCHEMBL25153540 | 0.79 | PDE10A (0.39) | PTPN11PIK3CAPDE10ARIOK2MAP4K1 | |
| SCHEMBL31396605 | 0.79 | PTPN11 (0.45) | PTPN11KCNH2PIK3CARET | |
| SCHEMBL31396592 | 0.78 | PTPN11 (0.48) | PTPN11KCNH2PIK3CAHTR6MAPT | |
| SCHEMBL31435901 | 0.78 | PTPN11 (0.46) | PTPN11KCNH2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425499-A1 | TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2024-12-26 | — | — | US | disclosed |
| WO-2023064218-A1 | TYRO3 INHIBITORS | Halia Therapeutics, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425499-A1 | TYRO3 INHIBITORS | TYRO3, TYR, TH | PTPN11 80/4885KCNH2 2638/4885PIK3CA 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.